Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00611884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 16 Week Randomised, Open-labelled, Four-armed, Treat-to-target, Parallel-group Trial Comparing SIBA D Once Daily, SIBA E Once Daily, SIBA D Monday, Wednesday and Friday and Insulin Glargine Once Daily, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment
Study identification
- NCT ID
- NCT00611884
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 245 participants
Conditions and interventions
Conditions
Interventions
- insulin degludec Drug
- insulin glargine Drug
- metformin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Jul 31, 2008
- Completion
- Jul 31, 2008
- Last update posted
- Mar 2, 2017
2008
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Inglewood | California | 90301 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90057 | — |
| Novo Nordisk Investigational Site | Redlands | California | 92374 | — |
| Novo Nordisk Investigational Site | Spring Valley | California | 91978 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32204 | — |
| Novo Nordisk Investigational Site | Idaho Falls | Idaho | 83404-7596 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60607 | — |
| Novo Nordisk Investigational Site | Chicago | Illinois | 60616 | — |
| Novo Nordisk Investigational Site | Springfield | Illinois | 62711 | — |
| Novo Nordisk Investigational Site | Greensboro | North Carolina | 27408 | — |
| Novo Nordisk Investigational Site | Medford | Oregon | 97504 | — |
| Novo Nordisk Investigational Site | Simpsonville | South Carolina | 29681 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75230 | — |
| Novo Nordisk Investigational Site | San Antonio | Texas | 78229 | — |
| Novo Nordisk Investigational Site | Newport News | Virginia | 23606 | — |
| Novo Nordisk Investigational Site | Renton | Washington | 98057 | — |
| Novo Nordisk Investigational Site | Milwaukee | Wisconsin | 53209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00611884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2017 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00611884 live on ClinicalTrials.gov.